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D Ford and DF Easton
Section ofEpidemiology, Institute ofCancer Research, Block D, 15 Cotswold Road, Belmont, Surrey SM2 SNG, UK.
Summary A number of genes are known to be involved in inherited susceptibility to breast and/or ovarian
cancer. In the context of high-risk families the most important genes are BRCAJ on chromosome 17q, which
is associated with a high penetrance of both breast and ovarian cancer, and BRCA2 on chromosome 13q,
which causes a high risk of breast cancer but a lower risk ofovarian cancer. Other high-risk cancer genes that
confer increased risks of breast or ovarian cancer in addition to other cancers include the hereditary
non-polyposis colorectal cancer genes and the TP53 gene, which causes breast cancer as part of the
Li-Fraumeni syndrome. The predisposing mutations in these genes are relatively rare in the population. More
common genes which are associated with an increased, but lower, risk of breast cancer are the ataxia-
telangiectasia gene and the HRASI gene. This paper reviews recent progress in mapping and cloning of these
susceptibility genes, and provides estimates of the cancer risks associated with each gene and the frequency of
predisposing mutations.
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An inherited component to common cancers has been
suspected for many years because of anecdotal reports of
families with large numbers of affected individuals. Both
breast and ovarian cancer were recognised as clustering in
some families over 100 years ago (Broca, 1866; Olshausen,
1877). More recently systematic epidemiological studies of
familial risks have demonstrated that most common cancers
occur more frequently in first-degree relatives of cancer
patients with the same type of cancer than in the general
population. The overall relative risk of breast or ovarian
cancer in first-degree relatives of individuals affected at the
same site is 2- to 3-fold (Houlston and Peto, 1995) and much
higher relative risks are observed if attention is restricted to
breast cancer cases occurring at an early age (Claus et al.,
1990a). (An age-at-onset effect has not been established for
ovarian cancer). Families with several cases of both types
have also been described (Lynch et al., 1972). The risk of
ovarian cancer is moderately increased, of the order 1.3- to
1.7-fold, in the relatives of breast cancer patients and vice
versa (Schildkraut et al., 1989; Goldgar et al., 1994a; Easton
et al., 1995; Peto et al., 1995), suggesting the existence of
genes predisposing to both cancers.
A number of segregation analyses on pedigrees ascertained
through a breast cancer proband have been performed and
most have provided evidence for the presence of a rare
dominant breast cancer gene conferring a high risk (e.g.
Claus et al., 1991). A segregation analysis of 518 families
ascertained through an ovarian cancer proband with at least
one affected relative also favoured a rare dominant gene
(Houlston et al., 1991).
The inherited basis of certain families with a high risk of
breast and/or ovarian cancer has now been confirmed with
the identification or localisation of susceptibility genes. These
genes, which are the principal subject of this review, are
summarised in Table I. The majority of large multiple case
families can now be attributed to BRCAJ or BRCA2.
BRCAJ on chromosome 17q, which increases susceptibility
Correspondence: D Ford. *The text is reproduced from a paper
given at the 29th Study Group of the Royal College of Obstetricians
and Gynaecologists on the Biology of Gynaecological Cancer in
October 1994 and included in the Proceedings 'Biology of
Gynaecological Cancer', edited by R Leake, MR Gore, published by
the RCOG Press in June 1995.
Received 7 December 1994; revised 10 April 1995; accepted 15 May
1995
to breast and ovarian cancer was identified by linkage in
1990 (Hall et al., 1990) and has recently been cloned (Miki et
al., 1994). BRCA2, a predominantly breast cancer gene, has
now been localised to chromosome 13q by linkage analysis
(Wooster et al., 1994). Other high risk cancer genes which
confer elevated risks of breast or ovarian cancer in addition
to other cancers include the genes responsible for the
hereditary non-polyposis colorectal cancer syndrome, which
predisposes predominantly to colorectal and endometrial
cancer but also has an associated increased ovarian cancer
risk (Leach et al., 1993; Watson and Lynch, 1993; Bronner et
al., 1994; Nicolaides et al., 1994; Papadopoulos et al., 1994)
and the TP53 gene on chromosome 17p, which causes
premenopausal breast cancer as part of the Li-Fraumeni
syndrome (Li et al., 1988; Malkin et al., 1990).
Predisposing mutations in these genes are all rare and are
therefore unlikely to account for more than a small minority
of total breast and ovarian cancer incidence except at very
young ages. The ataxia-telangiectasia gene (Gatti et al., 1988;
Swift et al., 1991) and the HRASI gene (or a closely linked
gene) (Krontiris et al., 1993) are more common genes which
increase susceptibility to breast cancer but to a far lesser
extent than BRCAJ, BRCA2 or TP53; these genes therefore
account for a small proportion of the familial breast cancer
risk but may account for a larger proportion of breast cancer
cases within the population.
The BRCAI gene
Localisation ofBRCA1
In 1990 Hall et al. reported the first convincing localisation
of a breast cancer gene (later -named BRCAJ) by genetic
linkage. In an analysis based on 23 families they obtained a
two-point LOD score of 3.28 at a recombination fraction of
0.14 from D17S74, a marker on chromosome 17q21, with an
estimated 40% of families linked. Linkage evidence was
restricted to families with a mean age of diagnosis of less
than 46 years (LOD = 5.98). Confirmation of linkage to
D17S74 was obtained by Narod et al. (1991) in three of five
families with hereditary breast-ovarian cancer. In this study
there were multiple individuals with ovarian cancer among
the apparent gene carriers providing convincing evidence for
a common predisposition to breast and ovarian cancer. Foll-
owing these two publications an international collaborative
group known as the Breast Cancer Linkage ConsortiumGenetics of breast and ovarian cancer
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Table I Genes known to predispose to breast or ovarian cancera
Risk of breast Risk of ovarian Other
Population cancer by age cancer by age associated
Gene Location frequency 50b 70b 50b 70b cancers
BRCAJ 17q21 0.0006 51%C 85%c 23%c 63%c Colon, prostate
BRCA2 13ql2-13 ?
TP53 17pl3.1 0.00005 50%
hMSH2
hMLHI
hPMSI
hPMS2
AT
2p22-2I
3p2l.3
2q31-33
7p22
1lq22-23
63%d <10%
No excess
? No excess ?
0.005 6% 17% No exces
HRASJ lip15.5 0.058 3% 8% ?
Sarcomas,
brain tumours,
adrenocortical,
leukaemias,
others
< 10% Colorectal
endometrial
gastric, others
ss All cancers?
Colorectal,
bladder,
leukaemia,
others
aIn three males with breast cancer, including two brothers, mutations in the androgen receptor gene
on Xql -12 have been found (Wooster et al., 1992; Lobaccaro et al., 1993). There is no evidence that
mutations in the androgen receptor cause female breast cancer. bRisks are in the absence of other
causes of death and apply to females only. Corresponding population risks in England and Wales are
1.5% and 4.8% for breast cancer and 0.3% and 1.0% for ovarian cancer. CRisks for BRCAJ assume
homogeneity of risk across families (see text). dBRCA2 confers a small excess risk ofmale breast cancer.
(BCLC) was established to pursue linkage to BRCAI and
other loci. The first BCLC study, which included data on 214
families, demonstrated overwhelming evidence for linkage of
breast and ovarian cancer to 17q and assigned BRCAI to a
region some 20 cM proximal to D17S74 (Easton et al., 1993).
Subsequent data convincingly localised BRCAJ to an interval
of less than 2 cM bounded by D17S857 and D17S78 (Kelsell
et al., 1993).
The cloning ofBRCA1
The BRCAJ gene has recently been identified by positional
cloning (Miki et al., 1994). It is composed of 22 coding exons
distributed over more than 100 kb of genomic DNA and
encodes a protein of 1863 amino acids. Interestingly BRCAJ
shows little homology to any previously identified genes, so
its function is as yet unclear. However, the amino terminal
region of this protein contains a zinc-finger domain, a motif
found in many nucleic acid-binding proteins, suggesting that
BRCAJ may regulate gene expression.
Germline mutations were initially detected in five of eight
families which demonstrated linkage to BRCAJ (Miki et al.,
1994) and in 4 of 44 breast and ovarian tumours (Futreal et
al., 1994). Mutations have now been reported in 80 patient
samples by an international collaboration (Shattuck-Eidens
et al., 1995). Sixty-three mutations, 38 of which were distinct,
were identified through a complete screen of the BRCAJ
gene. Three specific mutations appeared to be relatively com-
mon, occurring eight, seven and five times respectively. The
two most common mutations were then found in 17 addit-
ional patients using targeted screening. The majority of alter-
ations were frameshift or nonsense mutations which truncate
the protein product. In addition there were a number of
missense mutations. Not all BRCAI-linked families, however,
are due to alterations in the coding sequence, since a number
of families with clear evidence of linkage have not revealed
any abnormalities even when the entire coding sequence has
been examined by direct sequencing. The collaborative study
also identified a mutation in a splice site, and a family with
an inferred regulatory mutation (where the copy of BRCAJ
linked to the disease was not transcribed into RNA). Since a
variety of methods have been used to identify mutations, the
true proportions of mutations of different types are not yet
known.
The fact that many mutations are clearly inactivating sugg-
ests that BRCAJ acts as a tumour-suppressor gene. Under
this model, cancers in BRCAI-linked families result from the
inheritance of an inactivating mutation in one copy of the
gene followed by a somatic loss of the non-mutant (wild-
type) gene on the other chromosome. Support for this
hypothesis is provided by the fact that loss of heterozygosity
on 17q in breast and ovarian tumours in BRCAJ families
invariably involves the wild-type chromosome (Smith et al.,
1992; Kelsell et al., 1993).
Under the model for inherited cancer syndromes first pro-
posed by Knudson (1971) (and shown to be correct for a
number of syndromes including retinoblastoma (Huang et
al., 1988) and familial adenomatous polyposis (Groden et al.,
1991; Kinzler et al., 1991)) BRCAJ alterations should also be
important events (somatically) in the development of non-
hereditary (sporadic) cancer. Under this model hereditary
cancer would occur at an earlier age, on average, than
sporadic cancer, loss of heterozygosity would be seen in
sporadic tumours and the remaining copy of BRCAJ should
contain an inactivating mutation. Breast cancers in BRCAI-
linked families do occur at an earlier age than in the popula-
tion, though the effect is not so clear for ovarian cancer, and
loss of heterozygosity is observed in a high proportion
(30-70%) of sporadic breast and ovarian tumours (Cornelis
et al., 1993; Jacobs et al., 1993). However, the evidence for
inactivating mutations in sporadic breast and ovarian
tumours is limited. Futreal et al. (1994) examined 32 breast
and 12 ovarian cancer tumours (selected for loss of heter-
ozygosity at BRCAI) for mutations in the coding region of
BRCAJ. They detected four mutations, three in breast
cancers and one in an ovarian cancer, but all four mutations
were germline alterations and occurred in early-onset cases.
Two of the breast cancer cases had an affected first-degree
relative found retrospectively in their medical records; one
case had a mother with ovarian cancer and the second
patient had a sister with breast cancer diagnosed at age 34.
Although Merajver et al. (1995) have recently reported
somatic mutations in 4 out of 47 ovarian cancers, no somatic
mutations in breast cancer have been reported to date. There
are also no reports of homozygous deletions or translocat-
ions affecting BRCAJ in tumours. Evidence thus far, there-
fore, suggests that BRCAJ may not be critical in the develop-
ment of the majority of breast and ovarian cancers.Genetic heterogeneity
In the BCLC study a clear distinction was apparent between
breast-ovarian families and families containing breast cancer
only (Easton et al., 1993). All 57 families with at least one
case of ovarian cancer were estimated to be linked, with a
lower 95% confidence limit (CL) of 79% on the percentage
linked. In contrast only an estimated 45% of families with
multiple cases of breast cancer, but no ovarian cancer were
linked (95% CL 25-66%). Linkage was more likely if the
average age of breast cancer diagnosis in the family was
young, although the distinction between the young and older
age-at-onset families was not as striking as the age effect
observed by Hall et al. (1990).
Since the original BCLC study, there have been a number
of anecdotal reports of breast-ovarian families which are
inconsistent with linkage to BRCAJ. A pattern that has
emerged however, is that it is those families with male breast
cancer, some of which also contain ovarian cancer, which are
not linked to BRCAI. A recent analysis of 132 breast-ovarian
cancer families with no male breast cancer confirmed that the
majority, although possibly not all, of these are due to
BRCAJ (Narod et al., 1995). Overall an estimated 88% of
families were linked (95% CL 74-97%) and in the subgroup
of 81 families with at least two ovarian cancers 92% of
families were linked (95% CL 76-100%). There are few
families which contain multiple cases of ovarian cancer but
no breast cancer, but all the evidence suggests that most if
not all of these families are also caused by BRCAJ. Steichen-
Gersdorf et al. (1994) studied nine families with at least three
cases of ovarian cancer and no cases of breast cancer diag-
nosed below age 50. Seven of the nine families were com-
pletely consistent with linkage to BRCAJ.
In the original BCLC study only five families with any case
of male breast cancer were included and evidence for or
against linkage to BRCAJ was inconclusive. In a more recent
study of 22 families, each containing at least one male breast
cancer case, strong evidence against linkage to BRCA1 was
demonstrated and the best estimate of the percentage of
linked families was 0% with an upper 95% CL of 18%
(Stratton et al., 1994). Interestingly in the subgroup of 12
families containing male and female breast cancer and at
least one ovarian cancer the evidence against linkage was
also strong with an estimated 0% of families linked (95% CL
0-29%). Several of these families are now known to be due
to BRCA2 (see below).
Associated breast and ovarian cancer risks
In the future it should be possible to estimate directly the
cancer risks conferred by BRCAI by studying gene carriers
identified through large population-based studies. In the
meantime, estimates have been derived from the data coll-
ected on linkage families using two essentially independent
methods, namely maximising the LOD score over possible
penetrance functions and using the incidence of second breast
or ovarian cancers following a first breast cancer. Using
either approach the overall lifetime risk of breast or ovarian
cancer was estimated as close to 100% (Ford et al., 1994;
Easton et al., 1995). Using the maximum LOD score method
(assuming no heterogeneity of risk between families) the
estimated cumulative risk for breast cancer rose to 51% by
age 50 (95% CL 25-67%) and 85% by age 70 (95% CL
51-95%). The corresponding estimates for ovarian cancer
were 23% by age 50 (95% CL 5-38%) and 63% by age 70
(95% CL 25-82%). Up to age 60 the second cancer data
gave somewhat higher risks, possibly reflecting individual
variation in risk due to other genetic or environmental fac-
tors or a tendency to ascertain families with individuals with
double primary cancers, but neither the overall cumulative
risk by age 70 nor the site-specific risks by age 70 differed
between the studies. The largest BRCAJ family to be
reported in the literature, which contains some 30 breast
cancers and 20 ovarian cancers, has also been analysed using
lifetable analysis and provides further evidence for the high-
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lifetime risk estimates of breast and ovarian cancers (Goidgar
et al., 1994b). In this family the risks of breast and ovarian
cancer by age 70 were 73% and 65% respectively (DE Gold-
gar and CM Lewis, personal communication).
As predicted by the segregation analyses, the age-specific
incidence of breast cancer in BRCAJ mutation carriers fol-
lows a markedly different pattern from that seen in the
general population. The relative risk declines by an order of
magnitude over the age range 30-70 years. The results for
ovarian cancer are less clear, although there is some suggest-
ion of a decline in relative risk with age (Easton et al., 1995).
Simple inspection of the families which are likely to be
linked to BRCAJ suggests that the ovarian cancer risks are
not homogeneous across families. Some of the large linked
families contain only one or two cases of ovarian cancer,
while other families contain more ovarian cancers than breast
cancers. Easton et al. (1995) have shown that the observed
patterns of disease are better explained by a model with two
different susceptibility alleles (referred to as 'type 1, and 'type
2' alleles), one conferring a cumulative ovarian cancer risk of
26% by age 70 and the other conferring a cumulative ovarian
cancer risk of 85%. There was no evidence to suggest that
the breast cancer risk differed between families and under
this model the estimated breast cancer risk by age 70 was
76%. The second allele, conferring a high ovarian cancer
risk, was estimated to account for 11% of BRCAI mutations
and the first allele (with a lower ovarian cancer risk), the
remaining 89%. Some support for this allelic heterogeneity
was found by considering the risks of ovarian cancer in
individuals already affected with breast cancer, according to
whether the family was probably due to the 'type 1' or 'type
2' allele. The risk of ovarian cancer in women with a
previous breast cancer was higher in families with a posterior
probability of greater than 50% of being due to a 'type 2'
allele than in the remaining 'type 1' families, although only
by a factor of two as compared with an estimated 6-fold
difference in incidence rates in the heterogeneity analysis.
Now that BRCAJ has been cloned it may prove possible to
resolve the issue of heterogeneity by examining the disease
phenotypes associated with different types of mutations, but
it appears that large numbers of families will be required. In
the collaborative survey of mutations in BRCAI reported by
Shattuck-Eidens et al. (1995) there was not a statistically
significant difference in the distribution of the BRCAJ mutat-
ional spectra among low- and high-prevalence ovarian cancer
families.
It is also conceivable that there are BRCAJ mutations
which confer a much lower overall risk of cancer than sugg-
ested here and do not usually generate the large multiple-case
families suitable for linkage. If such mutations exist, then the
estimates presented here would only be relevant to the 'high-
risk' type families; however these are the families which are
currently being counselled on the basis of linkage data in
clinics.
It should be noted that all ovarian cancers due to BRCAJ
appear to be invasive epithelial tumours; there is no evidence
that BRCAJ can cause borderline or germ-cell tumours, or
benign cysts. Equally, there is no evidence that BRCAJ
mutations (or, in fact, any of the other gene defects discussed
here) result in lobular or ductal carcinoma in situ of the
breast. There is some suggestion that BRCAI-linked ovarian
cancers are more likely to be serous than mucinous (Narod,
1994).
Increased risks ofcolon andprostate cancer
Ford et al. (1994) studied 33 families with evidence for
linkage to BRCAJ to establish whether gene carriers are at
an increased risk of any cancer other than breast or ovarian
cancer. Eighty-seven other cancers were observed in individ-
uals with breast or ovarian cancer and their first-degree
relatives compared with 69.3 expected, based on national
incidence rates. There were statistically significant excesses of
colon cancer (P = 0.002) and prostate cancer (P = 0.006) but
no significant excesses or deficits for any other sites. TheGenetics of breast and ovarian cancer
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maximum likelihood estimate of the relative risk of colon
cancer in carriers compared with the general population was
4.11 (95% CL 2.36-7.15), giving an estimated cumulative
risk of colon cancer in gene carriers of the order of 6% by
age 70, compared with a 1-2% population risk. Although
there was some suggestion of a higher risk in females com-
pared with males this difference was non-significant. The
maximum likelihood estimate of the relative risk of prostate
cancer in carriers compared with the general population was
3.33 (95% CL 1.78-6.20). There was some suggestion that
the relative risk of prostate cancer in BRCA1 carriers is
higher in the European families than in the American
families, though this difference did not quite reach statistical
significance (relative risks 8.49 and 2.48 respectively,
P = 0.06). Since the incidence of prostate cancer is approx-
imately 3-fold higher in the US than in Europe, the estimated
absolute risk of prostate cancer is similar in the two popula-
tions and is approximately 8% by age 70. Such estimated
absolute risks of colon and prostate cancer in carriers are
probably too low tojustify any particular preventive strategy;
but this could alter if these cancers are found to be
associated with particular BRCAJ mutations.
The genefrequency ofBRCA1
In time it may be feasible to estimate the gene frequency of
BRCAJ by direct mutation testing of very large population-
based series of samples. However, a reasonable estimate of
the gene frequency has already been obtained indirectly by
combining the penetrance estimates of BRCAJ with the
results of two population-based studies ofcancer mortality in
the relatives of breast and ovarian cancer patients (D Ford et
al., in preparation). In a study of cancer mortality in the
first-degree relatives of 3295 breast cancer patients 49 ovarian
cancer deaths below age 70 were observed compared with
33.71 expected at national rates, that is an excess of 15.29
deaths (Peto et al., 1995). If BRCAJ were responsible for the
entire excess of ovarian cancer in relatives of breast cancer
patients, then, given the penetrance estimates for BRCAJ, the
overall frequency of BRCAI would be 0.00064. The assump-
tion that the familial association between breast and ovarian
cancer is mainly due to BRCAJ seems reasonable given the
results of the BCLC study alluded to previously. Although
BRCA2 mutations may also cause ovarian cancer (see below)
the risk is probably too low to have a measurable effect in
population-based studies. In a companion study of cancer
mortality in relatives of 1188 ovarian cancer patients 45
breast cancer deaths below age 70 were observed compared
with 33.63 expected (Easton et al., 1995). The same method
applied to this study would predict a gene frequency for
BRCAJ of 0.00052. The best estimate of the gene frequency,
taken as an average of the two estimates is 0.0006 (95% CL
0.0002-0.001). A gene frequency of 0.0006 corresponds to a
carrier frequency of 1 in 800. Even taking the upper 95% CL
only 1 in 500 women carries the mutation. Table II shows the
proportions of breast and ovarian cancers which would be
attributable to germline high penetrance BRCAI mutations
in each age group for possible gene frequencies, 0.0002,
0.0006 and 0.001. Much higher frequencies of the order of 1
in 300 are often cited, but these are derived from segregation
analyses of breast cancer (e.g. Claus et al., 1991) and do not
relate to BRCAJ specifically.
The BRCA2 gene
Localisation ofBRCA2
Wooster et al. (1994) have recently localised a second breast
cancer susceptibility gene (BRCA2) to 13ql2-13. They typed
15 families with multiple cases of early-onset breast cancer
and evidence against linkage to BRCAI. A multipoint LOD
score of 11.65 was obtained using markers D13S260 and
D13S267 with an estimated 74% (95% CL 35-97%) of
families linked. A map of the region is shown in Figure 1.
Single recombinants in breast cancer cases aged 43 and 39 in
two large families with convincing evidence for linkage place
BRCA2 telomeric to D13S289. One recombinant, also in a
large family, in a bilateral breast cancer diagnosed at ages 38
and 41 places the gene centromeric to D13S267.
Although the tumour-suppressor gene RB1 is in the same
region it is already clear that BRCA2 is not RBI since there
are a number of recombinants between RBI and the disease
in linked families. Other candidate genes within 13qll-14
include members of a family of tyrosine kinase genes that are
related to the FMS protooncogene (Rosnet et al., 1993) and
the FTEJ gene, which may act as an effector of the v-fos
oncogene and is a mammalian homologue of a yeast gene
13 cen
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Figure 1 Genetic map of chromosome 13q in the region of
BRCA2. Genetic distances between markers are given in cen-
timorgans (cM).
Table II Estimated percentage of cases due to germline BRCAI mutations
Genefrequency Genefrequency Genefrequency
0.0002 0.0006 0.001
Age group Breast Ovary Breast Ovary Breast Ovary
20-29 2.6 2.0 7.5 5.9 11.9 9.5
30-39 1.7 1.9 5.1 5.6 8.2 9.0
40-49 0.7 1.6 2.2 4.6 3.6 7.4
50-59 0.5 0.9 1.4 2.6 2.4 4.3
60-69 0.3 0.6 0.8 1.8 1.3 2.9
20-69 0.6 1.0 1.7 2.8 2.8 4.6involved in protein import into mitochondria (Kho. and
Zarbl, 1992). Preliminary evidence suggests that BRCA2 acts
as a tumour-suppressor gene. Collins et al. (1995) have
demonstrated loss of heterozygosity in seven out of eight
breast cancers from one large linked family, with all losses
involving the wild-type chromosome.
Associated cancer risks
Like BRCAJ, BRCA2 appears to confer a high risk of early-
onset breast cancer in females; in a previous segregation
analysis of the largest BRCA2-linked family (Utah 107) the
risk by age 70 was estimated as 63%, rising to 87% by age
80 (Bishop et al., 1988). However, the ovarian cancer risk
conferred by BRCA2 is likely to be much lower than the risk
conferred by BRCAI; in the two families showing the
strongest evidence of linkage to BRCA2 (multipoint LOD
score greater than 3.0) there are 49 reported cases of breast
cancer, including 39 under 50, and only three ovarian cancers
(excluding affecteds who do not carry the linked haplotype).
In contrast it seems likely that the male breast cancer risk in
carriers of BRCA2 mutations, although small, is probably
greater than in male BRCAJ mutation carriers. In the same
two families there were four cases of male breast cancer and
in a further three families which showed evidence of linkage
to BRCA2 there were single cases of affected males.
Collaborative studies will now be undertaken by the BCLC
to define more precisely the proportions of families of differ-
ent types linked to BRCA2, to estimate the penetrance of the
BRCA2 gene and to investigate the possibility that mutations
in BRCA2 cause other cancers.
Hereditary non-polyposis colorectal cancer genes
Hereditary non-polyposis colorectal cancer (HNPCC) is a
dominant familial cancer syndrome which predisposes to
colon cancer, and to a lesser extent, cancers at other sites
including endometrium, stomach, small bowel and ovary.
Watson and Lynch (1993) estimated the risk of ovarian
cancer in members of 23 HNPCC kindreds to be approx-
imately 4-fold greater than in the general population. The
true relative risk will be slightly higher since not all those
individuals studied will be carriers of the deleterious gene.
The median age of diagnosis was 40 years, which is con-
siderably lower than the median age of diagnosis in the
general population and in interesting contrast to ovarian
cancers within BRCAI-linked families. There was some
evidence that the ovarian cancer risk differed between
families.
It is now known that HNPCC can result from germline
mutations in a class of DNA repair genes originally identified
in yeast. To date, four such genes are known to cause
HNPCC, namely the hMSH2, hMLHI, hPMSI and hPMS2
genes on chromosomes 2p, 3p and 7p (Leach et al., 1993;
Bronner et al., 1994; Nicolaides et al., 1994; Papadopoulos et
al., 1994). However it is unclear whether all of these genes
confer an increased risk of ovarian cancer.
The frequency of these HNPCC mutations is the subject of
some debate. Some reports have suggested that as much as
20% of colorectal cancer could be due to mutations in these
genes. These estimates are based on the proportions ofcolor-
ectal tumours exhibiting the microsatellite instability pheno-
type, which is common in HNPCC families. However, most
of these tumours are likely to be sporadic and as yet there is
no evidence that this phenotype is invariably the result of
germline mutations in mismatch repair genes. Clinical studies
suggest that the HNPCC syndrome probably only accounts
for 1% or less of colorectal cancer (Bodmer et al., 1994;
Aaltonen et al., 1994), suggesting a population frequency of
the order of one in 10000.
The Li-Fraumeni syndrome and the TP53 gene
The Li-Fraumeni familial cancer syndrome (LFS) is a rare
dominant syndrome characterised by young onset sarcomas,
Geneics of breast andovaran cancer
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premenopausal breast cancers, brain tumours, adrenocortical
tumours and other cancers (Li et al., 1988). Germline mutat-
ions in the TP53 gene have been identified in over 50% of
LFS families and in a number of families with some but not
all of the features of the classical LFS (Malkin et al., 1990;
Eeles, 1993).
The absolute risk of breast cancer in mutation carriers has
not been estimated precisely but would appear to be at least
50% by age 50, with little increase in risk after menopause
(Li et al., 1988). Available evidence suggests that germline
TPS3 mutations account for a very small proportion of
breast cancer outside the LFS (or Li-Fraumeni-like syn-
drome). Although a splice-site TP53 mutation has been
found in one predominantly breast-ovarian cancer family
including two breast cancer cases diagnosed before age 35, an
ovarian cancer at 31 and a childhood choroid plexus tumour
(Jolly et al., 1994), it is now clear that most breast-ovarian
families are caused by BRCAJ and some, possibly all, of the
remainder are due to BRCA2. In population based studies of
breast cancer cases TPS3 germline mutations have been
found in less than 1% of cases, even at young ages (Borresen
et al., 1992; Sidransky et al., 1992).
Other breast cancer genes with high penetrance
There are a number of families characterised by early-onset
female breast cancer and/or male breast cancer which show
evidence against linkage to both BRCAJ and BRCA2
(Wooster et al., 1994; MR Stratton, R Wooster and DE
Goldgar, personal communication). It seems possible, there-
fore, that at least one more breast cancer gene with high
penetrance remains to be discovered. It should be noted,
however, that some of these apparently unlinked families will
be due to BRCAJ or BRCA2, but appear unlinked because
of young sporadic cases occurring by chance. Indeed BRCAJ
mutations have been found in a number of such families (DE
Goldgar, personal communication). A formal study to
estimate the proportion of high-risk families not accounted
for by BRCAJ and BRCA2 is currently being conducted by
the BCLC.
The ataxia-telangiectasia gene
Ataxia-telangiectasia (AT) is an autosomal recessive disorder
characterised by cerebellar ataxia, oculocutaneous telang-
iectasia, a hypersensitivity to ionising radiation and an in-
creased susceptibility to cancer (McKinnon, 1987; Sedgwick
and Boder, 1991). The frequency of the AT gene, which is
located on chromosome llq22-23, is likely to be of the
order of 0.005 (Easton, 1994), suggesting that about 1% of
the population are heterozygous for AT.
A number of studies have shown that female relatives of
AT patients are at an increased risk of breast cancer. Easton
(1994), in a review of four published studies (Swift et al.,
1987; Pippard et al., 1988; Borresen et al., 1990; Swift et al.,
1991), estimated that the relative risk of breast cancer to AT
heterozygotes is 3.9 fold (95% CL 2.1-7.2). A gene conferr-
ing such a low relative risk would not, on the whole give rise
to multiple early-onset case families. For example, assuming
a relative risk of 3.9 and a gene frequency of 0.005 Easton
(1994) estimated that only 1% of affected sister pairs aged 35
at diagnosis would be due to AT, the percentage rising to 3%
of sister pairs diagnosed at age 55. (This assumes a familial
relative risk of breast cancer of 5.3 at age 35, falling to 1.5 at
age 55, based on Claus et al., 1990b). The proportion of
families with three or more affected first-degree relatives
which could be attributed to AT would be even lower.
Assuming a constant relative risk of 3.9 across all ages and
a gene frequency of 0.005, the AT gene would account for
about 4% of breast cancers diagnosed below age 60 (95%
CL 1-13%). However, there is some suggestion that the
relative risk declines with age (Easton, 1994). If the AT gene
confers a relative risk of breast cancer of 9 below age 40, 3Genedcs of breast and ovarian cancer X _ D Ford and DF Easton
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between 40 and 60 and 1 above age 60, AT could be respons-
ible for 8% of cases under 40 and 2% of cases between 40
and 60.
HRASI
The proto-oncogene HRASJ is tightly linked to a minisatel-
lite locus, which has some 30 alleles of which four represent
94% of all alleles in whites, the remainder being rare (Capon
et al., 1983; Krontiris et al., 1986; Krontiris, 1990). A meta-
analysis of 23 studies has shown a highly significant associa-
tion of rare HRASJ alleles with cancer (Krontiris et al.,
1993). It is undetermined as yet whether the HRASJ gene
itself or a closely linked gene is responsible for the associa-
tion; if it is due to the HRASI gene, the mechanism underly-
ing the association is completely unclear. Sites for which
significant associations were found were breast, colorectum,
urinary bladder and acute leukaemia. The relative risk of
breast cancer associated with rare HRASJ alleles was 1.68
(95% CL 1.23-2.29), and the authors estimated that as many
as 1 in 11 breast cancers might be attributed to this factor.
Conclusions
Studies ofmultiple-case families have led to the identification
of highly penetrant genes which predispose to breast and
ovarian cancer. BRCAJ and BRCA2 appear to account for
the majority of large multiple-case families, but it is less clear
to what extent they account for the more common, smaller
breast and ovarian cancer families such as pairs of affected
relatives, since these could be due to lower penetrance genes.
For BRCAJ at least, it should now be possible to answer this
question directly.
From a genetic counselling standpoint it is already possible
to identify women in families linked to BRCAJ and to
counsel them on the basis of linkage data and reasonably
precise estimates of cancer risk. Now that BRCAJ has been
cloned it may not be long before direct testing for BRCAJ
mutations becomes practical on a routine basis in high-risk
women. However, it is already clear that mutations will be
widely scattered throughout the gene, thus testing on a large
scale is likely to be laborious and it will be difficult to
exclude the presence of a mutation. This, combined with the
rarity of BRCAI mutations makes it unlikely that testing in
the general population will be useful, other than for research
purposes. Intense efforts will now be made to clone BRCA2.
If BRCA2 is homologous to BRCAI or is one of the can-
didate genes already identified, BRCA2 may be cloned very
quickly, otherwise the time scale involved is indeterminate. In
the meantime risk estimates for BRCA2 should be available
soon, allowing women in BRCA2-linked families to have
counselling on the basis of genotyping.
Epidemiological studies are currently being conducted by
the BCLC to assess whether or not the risks of breast and
ovarian cancer in BRCA1 carriers are substantially modified
by other risk factors such as parity, age at first birth and oral
contraceptive use. From a practical point of view the most
important risk factor is oral contraceptive use. In the general
population long-term oral contraceptive use is known to
reduce substantially the risk of ovarian cancer (Parazzinni et
al., 1991) but to increase slightly the risk of breast cancer at
young ages (UK National Case-Control Study Group,
1990), so their use in BRCAJ carriers might cause a marked
increase or decrease in overall cancer risk. Similar studies of
BRCA2 carriers will also be important.
Taken together the high penetrance genes (BRCAJ,
BRCA2, TP53 and the HNPCC genes) are likely to account
for considerably less than 10% of all breast and ovarian
cancer cases in the population. Common susceptibility genes
could account for a much higher proportion ofcancers in the
general population but would necessarily confer much lower
lifetime risks. The HRASJ minisatellite locus is an example
of a common, low penetrant gene which causes breast cancer
but others may exist. The identification and understanding of
such genes (if they exist) would be of great practical impor-
tance, possibly leading to genetic testing as an adjunct to
screening for common cancers. However, low penetrant genes
will not cause multiple case families and may not even give
rise to a detectably increased risk in relatives of cancer
patients; thus they are likely to be difficult to detect by
finkage and will only be identified through associations of
cancer risk with other heritable phenotypes (as in the case of
AT), or through direct testing of candidate genes.
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